Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

Patients will receive a reduced-intensity conditioning regimen for 6 days that consists of
Fludarabine 150 mg/m2, Cyclophosphamide 29 mg/kg, and 3 Gy total body irradiation (TBI),
followed by HLA-haploidentical marrow from a family member on Day 0. On Days +3 and +4,
Cyclophosphamide 50 mg/kg will be infused for selective in vivo T cell depletion. Additional
post-grafting immune suppression will consist of mycophenolate mofetil and either tacrolimus
or sirolimus.

Non-mobilized peripheral blood mononuclear cells will be collected from donors on Day +6,
from which NK cells will be selected and infused into patients on Day +7.

Patients will be monitored for any transplant-related complications and will undergo disease
monitoring every three months for the first two years post-transplant. Research studies will
be conducted to follow the patient's immune status and quality of life post-transplant.

Inclusion Criteria:

1. No age restrictions

2. Only subjects who are not appropriate candidates for autologous or HLA-matched sibling
hematopoietic cell transplants (HCT) may be enrolled.

3. Diseases eligible

1. High Risk Neuroblastoma (NB): Must have progressed on or recurred after standard
frontline therapy including autologous HCT, or be ineligible for autologous HCT.

2. Ewing Sarcoma Family of Tumors (EWS) [includes both bone and soft tissue Ewing
and Peripheral Primitive Neuroectodermal Tumors (PNET)]. Must have progressed on
or recurred after standard frontline therapy which includes doxorubicin and
ifosfamide.

3. High-Risk Rhabdomyosarcoma (RMS) or Intermediate Risk Alveolar RMS recurring as
more than loco-regional tumor: Must have progressed on or recurred after standard
frontline therapy which includes chemotherapy with vincristine, actinomycin, and
cyclophosphamide AND either surgery or radiotherapy.

4. Osteosarcoma: Must have progressed or recurred after standard frontline therapy.
If first relapse, must have recurred with a) ≥ 4 lung nodules; b) bilateral lung
involvement; or c) relapse outside the lungs.

5. CNS tumors: High risk malignant brain tumors that are recurrent or refractory to
standard frontline therapy are eligible. Diagnoses include: Medulloblastoma,
primitive neuro-ectodermal tumor (PNET), ependymoma, high grade (grade 3 or 4)
glioma/astrocytoma, germ-cell tumor, or atypical teratoid-rhabdoid tumor (ATRT)

Exclusion Criteria

1. Rapidly-progressing disease prior to HCT, defined as clinical or radiographic evidence
of disease progression ≤ 3 weeks prior to protocol registration despite previous
achievement of stable or no disease (Appendix C & D) (Note: after disease eligibility
has been determined, additional imaging studies are not necessary during the three
weeks before the start of conditioning unless there are clinical concerns).

2. Patients who have reached radiation threshold limits and are excluded from receiving 3
Gy TBI.

3. Diffuse intrinsic pontine gliomas (DIPG) are excluded.

4. Performance status: Karnofsky or Lansky <60% Note: Patients who are unable to walk
because of paralysis, but who are up in a wheelchair, will be considered ambulatory
for the purpose of assessing the performance score

5. Patients, who in the opinion of the investigator, may not be able to comply with the
treatment plan or safety monitoring requirements of the study Page 16 of 86 Children's
Hospital of Wisconsin Medical College of Wisconsin PI: Monica S. Thakar, MD

6. Significant organ dysfunction that would prevent compliance with conditioning, GVHD
prophylaxis, or would severely limit the probability of survival, defined as:

1. Cardiac: For patients not taking inotropic medications and who do not have
cardiac failure requiring therapy: Symptomatic coronary artery disease or
ejection fraction <35% or, if unable to obtain ejection fraction, shortening
fraction of <26%. If shortening fraction is <26% a cardiology consult is required
with the PI having final approval of eligibility. For patients taking inotropic
medications: Patients displaying corrected cardiac function will be eligible,
i.e., patients who take inotropic medications to maintain EF ≥ 35% and SF≥ 26%
cardiac function eligibility.

2. Pulmonary: DLCO <40% TLC <40%, FEV1 <40% and/or receiving supplementary
continuous oxygen

3. Liver: Patient with clinical or laboratory evidence of liver disease will be
evaluated for the cause of liver disease, its clinical severity in terms of liver
function, bridging fibrosis, and the degree of portal hypertension. The patient
will be excluded if he/she is found to have fulminant liver failure, cirrhosis of
the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal
varices, a history of bleeding esophageal varices, hepatic encephalopathy,
uncorrectable hepatic synthetic dysfunction evinced by prolongation of the
prothrombin time, ascites related to portal hypertension, bacterial or fungal
liver abscess, biliary obstruction, chronic viral hepatitis with total serum
bilirubin >3mg/dL, or symptomatic biliary disease

7. Patients with serious active infections

8. HIV seropositive patients

9. Patients with poorly controlled hypertension despite multiple antihypertensive
medications

10. Fertile females who are unwilling to use contraceptive techniques during and for the
twelve months following treatment, as well as females who are pregnant or actively
breast feeding

11. Fertile males who are unwilling to use contraceptive techniques during and for the
twelve months following treatment

12. Life expectancy severely limited by diseases other than malignancy

13. Patients who have received a prior allogeneic HCT are ineligible

DONOR SELECTION An Unrelated Donor Search is not required for entry on this trial. Lack of
HLA-matched related or unrelated donors is not a requirement for entry on this trial.

A. Inclusion Criteria

1. Related, HLA-haploidentical donors who are identical for one HLA haplotype and
mismatched for any number of HLA-A, -B, -C, DRB1 or DQB1 loci of the unshared
haplotype.

2. Marrow will be prioritized as the hematopoietic stem cell source of choice. In cases
where adequate stem cells cannot be collected, fresh (preferred) or cryopreserved
donor PBSC may be substituted. In the case that PBSC are used, the donor must be 18
years of age or older.

3. HLA-haploidentical donor selection will be based on standard institutional criteria;
otherwise no specific prioritization will be made amongst the suitable available
donors.

B. Exclusion Criteria

1. Children less than 12 years of age (marrow) or less than 18 years of age (PBSC).

2. Children greater than or equal to 12 years of age who have not provided informed
assent in the presence of a parent and an Attending physician who is not a member of
the recipient's care team

3. Children greater than or equal to 12-17.9 years of age who have inadequate peripheral
vein access to safely undergo apheresis

4. Donors unable or unwilling to undergo marrow harvest or PBSC collection for the
initial HCT, storage of autologous blood prior to marrow harvest (if applicable), or
apheresis one week after marrow harvest

5. Donors who are not expected to meet the minimum target dose of marrow cells (1 x 108
total nucleated cells/kg recipient weight) for the initial marrow HCT or PBSC
transplant (5.0 x 106 CD34/kg recipient weight). The average nucleated cell content of
harvested marrow is 22 x 106 nucleated cells/mL or 220 x 108 total nucleated
cells/Liter

6. HIV-positive donors

7. Donors who are cross-match positive with recipient